Clinical Trials Directory

Trials / Completed

CompletedNCT04900090

Tahiti-families: Polynesian Families of Gout Patients

Tahiti-families: From Genetic to Phenotype Study of Polynesian Families of Gout Patients

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
33 (actual)
Sponsor
Lille Catholic University · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Accepted

Summary

Gout is a chronic disease caused by the deposit of monosodium urate (MSU) crystals in body tissues secondary to hyperuricemia. Patients with gout suffer severe attacks of acute joint pain. As the disease progresses, the joint pain becomes chronic and associated with disabling and deformative manifestations called tophus. This disease is strongly associated with several comorbidities such as cardiovascular disease and chronic kidney failure. Gout is a very common disease, which is affecting 0.9% of the adult population in France and nearly 4% of the North-American population. Data from New Zealand show a particularly high prevalence of gout among Polynesians (minority populations in New Zealand and other islands of the South Pacific) that would be explained by genetic susceptibility and frequently interrelated metabolic diseases. Data on the Polynesian population in New Caledonia suggest prevalence figures close to 7% and prevalence in French Polynesia is assumed to be higher. International genomic studies of gout and hyperuricaemia have identified alleles associated with the occurrence of gout. The aim is to focus on families with several gouty members (numerous in French Polynesia, and geographically clustered) in order to enable the study of individuals with monogenic gout or with a low number of variants (= cases) determining in the occurrence of gout, as well as a non-gouty family member (= controls). Dual-energy CT scan (DECT) allows identification and quantification of UMS crystal deposits in the tissue. The volume of crystals correlates not only with the inflammatory activity of the disease but also with the comorbidities that complicate it. Dual-energy scanning has shown the presence of UMS crystals in some hyperuricemic individuals, which could help to identify those individuals most at risk of developing the disease as they already have the stigma of sub-clinical inflammatory activity.

Conditions

Interventions

TypeNameDescription
OTHEREpidemiological study* Clinical phenotypic assessment and neurosensory measures * Biological, genetic and metabolomic evaluation * Questionnaires (quality of life, gout, life habit, comorbidities) * Morphological evaluation by Dual-energy CT scan

Timeline

Start date
2021-05-25
Primary completion
2021-08-31
Completion
2021-08-31
First posted
2021-05-25
Last updated
2024-03-06

Locations

1 site across 1 country: French Polynesia

Source: ClinicalTrials.gov record NCT04900090. Inclusion in this directory is not an endorsement.